The present invention relates to compounds and methods useful as inhibitors of phosphodiesterase 4 (PDE4) for the treatment or prevention of disease.

There is provided herein a compound of formula I,

##STR00001##

wherein R.sup.1, R.sup.2, n, X, Q, L, m, R.sup.3 and p are as defined herein, which compounds are useful in the treatment of treatment of diseases characterised by impaired signalling of neurotrophins and/or other trophic factors, such as Alzheimer's disease and the like.

There is provided herein a compound of formula I,

##STR00001##

wherein R.sup.1, R.sup.2, n, X, Q, L, m, R.sup.3 and p are as defined herein, which compounds are useful in the treatment of treatment of diseases characterised by impaired signalling of neurotrophins and/or other trophic factors, such as Alzheimer's disease and the like.

The invention relates to compounds which are suitable for use in electronic devices, and to electronic devices, in particular organic electroluminescent devices, containing said compounds.

Provided are: a novel nucleating agent capable of imparting excellent transparency to synthetic resins; a synthetic resin composition containing the same; and a molded object of the synthetic resin composition. The nucleating agent contains at least one triazine compound represented by Formula (1), wherein Ar.sup.1, Ar.sup.2 and Ar.sup.3 each independently represent an unsubstituted phenyl group or a substituted phenyl group. In Formula (1), for example, the number of substituents of the substituted phenyl group is preferably 1, and Ar.sup.1, Ar.sup.2 and Ar.sup.3 are preferably all different groups.

##STR00001##

Provided are: a novel nucleating agent capable of imparting excellent transparency to synthetic resins; a synthetic resin composition containing the same; and a molded object of the synthetic resin composition. The nucleating agent contains at least one triazine compound represented by Formula (1), wherein Ar.sup.1, Ar.sup.2 and Ar.sup.3 each independently represent an unsubstituted phenyl group or a substituted phenyl group. In Formula (1), for example, the number of substituents of the substituted phenyl group is preferably 1, and Ar.sup.1, Ar.sup.2 and Ar.sup.3 are preferably all different groups.

##STR00001##

Provided are a nonaqueous electrolyte capable of providing a nonaqueous electrolyte energy storage device with reduced direct current resistance and an increased capacity retention ratio after charge-discharge cycles, a nonaqueous electrolyte energy storage device including such a nonaqueous electrolyte, and a method for producing such a nonaqueous electrolyte energy storage device. One mode of the present invention is a nonaqueous electrolyte for an energy storage device, containing an additive represented by the following Formula (1) or Formula (2). In Formula (1), R.sup.1 to R.sup.4 are each independently a hydrogen atom or a group represented by —NR.sup.a.sub.2, —OR.sup.a, —SR.sup.a, etc., with the proviso that at least one of R.sup.1 to R.sup.4 is a group represented by —OR.sup.a, —SR.sup.a, —COOR.sup.a, —COR.sup.a, —SO.sub.2R.sup.a, or —SO.sub.3R.sup.a. In Formula (2), R.sup.5 to R.sup.7 are each independently a hydrogen atom or a group represented by —NR.sup.b.sub.2, —OR.sup.b, or —SR.sup.b, with the proviso that at least one of R.sup.5 to R.sup.7 is a group represented by —SR.sup.b.

##STR00001##

Provided are a nonaqueous electrolyte capable of providing a nonaqueous electrolyte energy storage device with reduced direct current resistance and an increased capacity retention ratio after charge-discharge cycles, a nonaqueous electrolyte energy storage device including such a nonaqueous electrolyte, and a method for producing such a nonaqueous electrolyte energy storage device. One mode of the present invention is a nonaqueous electrolyte for an energy storage device, containing an additive represented by the following Formula (1) or Formula (2). In Formula (1), R.sup.1 to R.sup.4 are each independently a hydrogen atom or a group represented by —NR.sup.a.sub.2, —OR.sup.a, —SR.sup.a, etc., with the proviso that at least one of R.sup.1 to R.sup.4 is a group represented by —OR.sup.a, —SR.sup.a, —COOR.sup.a, —COR.sup.a, —SO.sub.2R.sup.a, or —SO.sub.3R.sup.a. In Formula (2), R.sup.5 to R.sup.7 are each independently a hydrogen atom or a group represented by —NR.sup.b.sub.2, —OR.sup.b, or —SR.sup.b, with the proviso that at least one of R.sup.5 to R.sup.7 is a group represented by —SR.sup.b.

##STR00001##

There is provided herein a compound of formula (I) wherein R.sup.1, R.sup.2, n, X, Q, L, m, R.sup.3 and p are as defined herein, which compounds are useful in the treatment of treatment of diseases characterised by impaired signalling of neurotrophins and/or other trophic factors, such as Alzheimer's disease and the like. ##STR00001##

There is provided herein a compound of formula (I) wherein R.sup.1, R.sup.2, n, X, Q, L, m, R.sup.3 and p are as defined herein, which compounds are useful in the treatment of treatment of diseases characterised by impaired signalling of neurotrophins and/or other trophic factors, such as Alzheimer's disease and the like. ##STR00001##